Clinical Trial Update: A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of LY2510924 plus sunitinib in metastatic clear cell renal cell carcinoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• LY2510924 (LY2510924)
• Sunitinib (sunitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-07-23